Skip to main content

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Latest News

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After ProgressionNews & Conference Highlights

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression

April 2, 2026
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Navigating Second-Line Treatment Decisions in EGFR+ NSCLCExpert Insights

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC

April 1, 2026
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLCNews & Conference Highlights

Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC

March 30, 2026

Latest News

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After ProgressionNews & Conference Highlights

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression

April 2, 2026
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Navigating Second-Line Treatment Decisions in EGFR+ NSCLCExpert Insights

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC

April 1, 2026
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLCNews & Conference Highlights

Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC

March 30, 2026

Expert Insights

View All

High-level synthesis, interpretation, and clinical framing from established thought leaders.

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Navigating Second-Line Treatment Decisions in EGFR+ NSCLCExpert Insights

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC

April 1, 2026
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLCExpert Insights

How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC

March 26, 2026
Ongoing Research to Watch in EGFR-Mutated NSCLC
Ongoing Research to Watch in EGFR-Mutated NSCLCExpert Insights

Ongoing Research to Watch in EGFR-Mutated NSCLC

March 13, 2026
Resistance Mechanisms in EGFR-Mutated NSCLC
Resistance Mechanisms in EGFR-Mutated NSCLCExpert Insights

Resistance Mechanisms in EGFR-Mutated NSCLC

March 13, 2026

News & Conference Highlights

View All

Rapid, curated interpretation of emerging data.

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After ProgressionNews & Conference Highlights

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression

April 2, 2026
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLCNews & Conference Highlights

Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC

March 30, 2026
Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC
Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLCNews & Conference Highlights

Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC

March 27, 2026
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLCNews & Conference Highlights

Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC

March 27, 2026

Emerging Voices in EGFR Care

View All

Highlight next-generation oncologists with fresh, pragmatic viewpoints.

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MScEmerging Voices in EGFR Care

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

November 14, 2025

How I Treat

View All

Practical, case-based, scenario-based, decision-oriented content.

56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen
56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 RegimenHow I Treat

56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen

May 2, 2025

Clinical Updates Calendar

Mo
Tu
We
Th
Fr
Sa
Su
Anticipated Decisions
Approvals
Conferences
Data Readouts
Designations
Events This Month

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

© 2026 MJH Life Sciences. All rights reserved.

Home
Clinical Updates Calendar
View All Resources